Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development and Validation of an RP-HPLC Method for Determination of Atorvastatin and its Hydroxyl Metabolites in Human Plasma

Author(s): Dagmara Sowińska, Alicja Pogorzelska, Marlena Rakicka, Justyna Sznura, Justyna Janowska, Patrycja Gorzycka, Mateusz Malak and Marta Karażniewicz-Łada*

Volume 16, Issue 3, 2020

Page: [238 - 245] Pages: 8

DOI: 10.2174/1573412914666180912110154

Price: $65

Abstract

Background: Atorvastatin (AT) belongs to cholesterol-lowering agents, commonly used in patients with an increased risk of cardiovascular disease. The drug, as well as its hydroxyl metabolites, exhibit pharmacological activity, and their plasma levels may be helpful in the assessment of the therapeutic effectiveness.

Objective: Development and validation of a fast and reproducible RP-HPLC method with UV detection for the simultaneous determination of atorvastatin and its active metabolites, para-hydroxy-atorvastatin (p-OH-AT) and ortho-hydroxy-atorvastatin (o-OH-AT) in human plasma.

Methods: Optimal conditions of chromatographic separation of the analytes, as well as rosuvastatin, chosen as an internal standard, were studied. The absorbance of the compounds was measured at λ=248 nm. Validation of the method was performed. The usefulness of the method was confirmed for determination of the analytes in plasma of patients treated with the drug.

Results: Total peak separation was achieved at LiChrospher 100 RP-18 column with a mobile phase composed of methanol and water (1:1,v:v) and a flow rate of 1.2 ml/min. The method was linear in the ranges of 0.025 - 1.0 μg/ml for AT, o-OH-AT and p-OH-AT. Intra- and inter-assay precision expressed as relative standard deviation was ≤13% for AT, ≤12% for p-OH-AT and ≤11% for o-OH-AT. Intraand inter-day accuracy of the method, expressed as a relative error, was ≤15%.

Conclusion: The elaborated HPLC method is specific, repeatable, reproducible, adequately accurate and precise and fulfills the validation requirements for the bioanalytical method. The method was successfully applied for analysis of atorvastatin and its o-hydroxy metabolite in plasma of patients treated with the drug.

Keywords: Atorvastatin, HPLC-UV, ortho-hydroxy-atorvastatin, para-hydroxy-atorvastatin, validation, human plasma.

« Previous Next »
Graphical Abstract

[1]
Ravnskov, U. Is atherosclerosis caused by high cholesterol? QJM, 2002, 95(6), 397-403.
[http://dx.doi.org/10.1093/qjmed/95.6.397] [PMID: 12037248]
[2]
Gardner, A.W.; Bright, B.C.; Ort, K.A.; Montgomery, P.S. Dietary intake of participants with peripheral artery disease and claudication. Angiology, 2011, 62(3), 270-275.
[http://dx.doi.org/10.1177/0003319710384395] [PMID: 21406424]
[3]
Ma, Y.; Li, Y.; Chiriboga, D.E.; Olendzki, B.C.; Hebert, J.R.; Li, W.; Leung, K.; Hafner, A.R.; Ockene, I.S. Association between carbohydrate intake and serum lipids. J. Am. Coll. Nutr., 2006, 25(2), 155-163.
[http://dx.doi.org/10.1080/07315724.2006.10719527] [PMID: 16582033]
[4]
Harris, S.K.; Roos, M.G.; Landry, G.J. Statin use in patients with peripheral arterial disease. J. Vasc. Surg., 2016, 64(6), 1881-1888.
[http://dx.doi.org/10.1016/j.jvs.2016.08.094] [PMID: 27871503]
[5]
Delgado, G.; Naves, M. Compliance and echographic carotid plaque evolution in patients with acute ischemic stroke treated with atorvastatin according to usual care. Vascular, 2014, 22(3), 218-220.
[http://dx.doi.org/10.1177/1708538113478751] [PMID: 23518842]
[6]
Stern, R.H.; Yang, B.B.; Hounslow, N.J.; MacMahon, M.; Abel, R.B.; Olson, S.C. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol., 2000, 40(6), 616-623.
[http://dx.doi.org/10.1002/j.1552-4604.2000.tb05987.x] [PMID: 10868312]
[7]
Athyros, V.G.; Mikhailidis, D.P.; Papageorgiou, A.A.; Symeonidis, A.N.; Mercouris, B.R.; Pehlivanidis, A.; Bouloukos, V.I.; Elisaf, M. GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr. Med. Res. Opin., 2004, 20(5), 627-637.
[http://dx.doi.org/10.1185/030079904125003421] [PMID: 15171226]
[8]
Schaefer, E.J.; McNamara, J.R.; Tayler, T.; Daly, J.A.; Gleason, J.L.; Seman, L.J.; Ferrari, A.; Rubenstein, J.J. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am. J. Cardiol., 2004, 93(1), 31-39.
[http://dx.doi.org/10.1016/j.amjcard.2003.09.008] [PMID: 14697462]
[9]
Adams, S.P.; Tsang, M.; Wright, J.M. Lipid lowering efficacy of atorvastatin. Cochrane Database Syst. Rev., 2012. 12CD008226
[PMID: 23235655]
[10]
Duman, I. Role of Pharmacogenetics on Response to Statins: A Genotype-Based Approach to Statin Therapy Outcome. J. Cardiol. Ther., 2014, 1(6), 111-120.
[11]
Karazniewicz-Lada, M.; Glowka, A.; Mikolajewski, J.; Przyslawski, J. Genetic and non-genetic determinants of the pharmacological activity of statins. Curr. Drug Metab., 2016, 17(9), 877-896.
[http://dx.doi.org/10.2174/1389200217666160919104241] [PMID: 27654899]
[12]
Guihen, E.; Sisk, G.D.; Scully, N.M.; Glennon, J.D. Rapid analysis of atorvastatin calcium using capillary electrophoresis and microchip electrophoresis. Electrophoresis, 2006, 27(12), 2338-2347.
[http://dx.doi.org/10.1002/elps.200500899] [PMID: 16786480]
[13]
Sharaf El-Din, M.M.K.; Salama, F.M.M.; Nassar, M.W.I.; Attia, K.A.M.; Kaddah, M.M.Y. Validated spectrofluorimetric method for the determination of atorvastatin in pharmaceutical preparations. J. Pharm. Anal., 2012, 2(3), 200-205.
[http://dx.doi.org/10.1016/j.jpha.2012.01.005] [PMID: 29403743]
[14]
Korany, M.A.; Hewala, I.I.; Abdel-Hay, K.M. Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques. J. AOAC Int., 2008, 91(5), 1051-1058.
[PMID: 18980118]
[15]
Zarghi, A.; Shafaati, A.; Foroutan, S.M.; Khoddam, A. A simple and rapid HPLC method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies. Arzneimittelforschung, 2005, 55(8), 451-454.
[PMID: 16149712]
[16]
Porwal, P.K.; Talele, G.S. Development of Validated HPLC-UV Method for Simultaneous Determination of Metformin, Amlodipine, Glibenclamide and Atorvastatin in Human Plasma and Application to Protein Binding Studies. Bull. Fac. Pharm. Cairo Univ., 2017, 55(1), 129-139.
[http://dx.doi.org/10.1016/j.bfopcu.2016.10.002]
[17]
Shah, Y.; Iqbal, Z.; Ahmad, L.; Khan, A.; Khan, M.I.; Nazir, S.; Nasir, F. Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2011, 879(9-10), 557-563.
[http://dx.doi.org/10.1016/j.jchromb.2011.01.004] [PMID: 21324753]
[18]
Bahrami, G.; Mohammadi, B.; Mirzaeei, S.; Kiani, A. Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 826(1-2), 41-45.
[http://dx.doi.org/10.1016/j.jchromb.2005.08.008] [PMID: 16150657]
[19]
Cai, L.; Zheng, Z.; Wang, X.; Tang, L.; Mai, L.; He, G.; Lei, H.; Zhong, S. Simultaneous Determination of Atorvastatin and Its Metabolites in Human Plasma by UPLC-MS/MS. Anal. Methods, 2017, 9(6), 1038-1045.
[http://dx.doi.org/10.1039/C6AY03113G]
[20]
Guillén, D.; Cofán, F.; Ros, E.; Millán, O.; Cofán, M.; Rimola, A.; Brunet, M. Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry. Anal. Bioanal. Chem., 2009, 394(6), 1687-1696.
[http://dx.doi.org/10.1007/s00216-009-2852-3] [PMID: 19506841]
[21]
Hermann, M.; Christensen, H.; Reubsaet, J.L.E. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal. Bioanal. Chem., 2005, 382(5), 1242-1249.
[http://dx.doi.org/10.1007/s00216-005-3266-5] [PMID: 15933849]
[22]
Partani, P.; Verma, S.M.; Gurule, S.; Khuroo, A.; Monif, T. Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(-) electrospray tandem mass spectrometry. J. Pharm. Anal., 2014, 4(1), 26-36.
[http://dx.doi.org/10.1016/j.jpha.2013.09.007] [PMID: 29403866]
[23]
Leung, C-H.; Zhong, H-J.; Yang, H.; Cheng, Z.; Chan, D.S-H.; Ma, V.P-Y.; Abagyan, R.; Wong, C-Y.; Ma, D-L. A metal-based inhibitor of tumor necrosis factor-α. Angew. Chem. Int. Ed. Engl., 2012, 51(36), 9010-9014.
[http://dx.doi.org/10.1002/anie.201202937] [PMID: 22807261]
[24]
Wang, W.; Vellaisamy, K.; Li, G.; Wu, C.; Ko, C-N.; Leung, C-H.; Ma, D-L. Development of a Long-Lived Luminescence Probe for Visualizing β-Galactosidase in Ovarian Carcinoma Cells. Anal. Chem., 2017, 89(21), 11679-11684.
[http://dx.doi.org/10.1021/acs.analchem.7b03114] [PMID: 28969424]
[25]
Vellaisamy, K.; Li, G.; Ko, C-N.; Zhong, H-J.; Fatima, S.; Kwan, H-Y.; Wong, C-Y.; Kwong, W-J.; Tan, W.; Leung, C-H.; Ma, D.L. Cell imaging of dopamine receptor using agonist labeling iridium(iii) complex. Chem. Sci. (Camb.), 2017, 9(5), 1119-1125.
[http://dx.doi.org/10.1039/C7SC04798C] [PMID: 29675156]
[26]
Martins, G.V.; Tavares, A.P.M.; Fortunato, E.; Sales, M.G.F. Paper-Based Sensing Device for Electrochemical Detection of Oxidative Stress Biomarker 8-Hydroxy-2′-deoxyguanosine (8-OHdG) in Point-of-Care. Sci. Rep., 2017, 7(1), 14558.
[http://dx.doi.org/10.1038/s41598-017-14878-9] [PMID: 29109407]
[27]
Draft Guidance for Industry on Bioanalytical Method Validation; Availability. https://www.federalregister.gov/documents/2013/09/13/2013-22309/draft-guidance-for-industry-on-bioanalytical-method-validation-availability (accessed Feb 28, 2018)

Rights & Permissions Print Cite
Article Metrics
24
© 2024 Bentham Science Publishers | Privacy Policy